An Independent Director since April 2011, George brings his extensive experience in drug development and biotechnology to the table. As head of the clinical program at the Ludwig Institute for Cancer Research and as Principal Investigator on the earliest clinical studies of haemopoietic growth factors, George was involved in Victoria’s earliest foray into biotechnology. From 1991 to 2002, he worked for US biotechnology pioneer, and now one of the world’s leading independent biotechnology companies, Amgen. In this company, he rose to become Senior Vice President of Development and Chief Medical Officer in 1999. George is Chair of the Board of GBS Bioventures, Board Member and Chair of the Scientific Advisory Board of Symbio in Japan, Board Member of the Cancer Therapeutics CRC, member of the commercialisation committee at the WEHI and Deputy Chair of the Health Forum of the ATSE. He also recently completed terms as Deputy Chair of the Victorian Comprehensive Cancer Centre, Board Member of Therapeutic Innovation Australia and Chair of its Virtual Pharma Committee.
As Biomedical Research Victoria starts its next phase – growing member numbers, fostering collegiality and promoting Victoria nationally and internationally as the first choice for health and medical research, collaborations, translation and innovation – Dr George Morstyn is the ideal champion for our cause.